Lundin Law PC, a shareholder rights firm, announces a class action lawsuit has been filed against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) concerning possible violations of federal securities laws between February 10, 2015 and November 3, 2016 inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, are encouraged to contact the firm in advance of the January 5, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at firstname.lastname@example.org.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, Teva made false and/or misleading statements and/or failed to disclose that: Teva engaged in conduct that would result in a Department of Justice (“DOJ”) antitrust investigation; that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against the Company by the end of 2016 for suspected price collusion; that Teva lacked effective internal controls; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Teva, to determine whether they unlawfully colluded with each other to fix generic drug prices.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107006143/en/